These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 27594539)

  • 1. PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia.
    Alonso R; Mata P; Muñiz O; Fuentes-Jimenez F; Díaz JL; Zambón D; Tomás M; Martin C; Moyon T; Croyal M; Thedrez A; Lambert G
    Atherosclerosis; 2016 Nov; 254():249-253. PubMed ID: 27594539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The different relations of PCSK9 and Lp(a) to the presence and severity of atherosclerotic lesions in patients with familial hypercholesterolemia.
    Cao YX; Liu HH; Sun D; Jin JL; Xu RX; Guo YL; Wu NQ; Zhu CG; Li S; Zhang Y; Sun J; Li JJ
    Atherosclerosis; 2018 Oct; 277():7-14. PubMed ID: 30170223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between lipoprotein (a) and proprotein convertase substilisin/kexin type 9 in patients with heterozygous familial hypercholesterolemia: A case-control study.
    Sun D; Li S; Zhao X; Wu NQ; Zhu CG; Guo YL; Gao Y; Qing P; Cui CJ; Liu G; Sun J; Dong Q; Li JJ
    Metabolism; 2018 Feb; 79():33-41. PubMed ID: 29129821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
    Afanasieva OI; Ezhov MV; Razova OA; Afanasieva MI; Utkina EA; Pokrovsky SN
    Atherosclerosis; 2018 Oct; 277():477-482. PubMed ID: 30270088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoprotein(a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolaemia.
    Vongpromek R; Bos S; Ten Kate GJ; Yahya R; Verhoeven AJ; de Feyter PJ; Kronenberg F; Roeters van Lennep JE; Sijbrands EJ; Mulder MT
    J Intern Med; 2015 Aug; 278(2):166-73. PubMed ID: 25487646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations.
    Tada H; Kawashiri MA; Yoshida T; Teramoto R; Nohara A; Konno T; Inazu A; Mabuchi H; Yamagishi M; Hayashi K
    Circ J; 2016; 80(2):512-8. PubMed ID: 26632531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achilles tendon xanthomas are associated with the presence and burden of subclinical coronary atherosclerosis in heterozygous familial hypercholesterolemia: A pilot study.
    Mangili LC; Miname MH; Silva PRS; Bittencourt MS; Rocha VZ; Mangili OC; Salgado Filho W; Chacra AP; Jannes CE; Pereira AC; Santos RD
    Atherosclerosis; 2017 Aug; 263():393-397. PubMed ID: 28499609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coronary Artery Calcium and Cardiovascular Events in Patients With Familial Hypercholesterolemia Receiving Standard Lipid-Lowering Therapy.
    Miname MH; Bittencourt MS; Moraes SR; Alves RIM; Silva PRS; Jannes CE; Pereira AC; Krieger JE; Nasir K; Santos RD
    JACC Cardiovasc Imaging; 2019 Sep; 12(9):1797-1804. PubMed ID: 30448145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between plasma proprotein convertase subtisilin/kexin type 9 concentration and coronary artery calcification.
    Zhao X; Zhang HW; Li S; Zhang Y; Xu RX; Zhu CG; Wu NQ; Guo YL; Qing P; Li XL; Liu G; Dong Q; Sun J; Li JJ
    Ann Clin Biochem; 2018 Jan; 55(1):158-164. PubMed ID: 28166668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VLDL (Very-Low-Density Lipoprotein)-Apo E (Apolipoprotein E) May Influence Lp(a) (Lipoprotein [a]) Synthesis or Assembly.
    Croyal M; Blanchard V; Ouguerram K; Chétiveaux M; Cabioch L; Moyon T; Billon-Crossouard S; Aguesse A; Bernardeau K; Le May C; Flet L; Lambert G; Hadjadj S; Cariou B; Krempf M; Nobécourt-Dupuy E
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):819-829. PubMed ID: 32078365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of lipoprotein(a) levels in familial hypercholesterolemia and coronary artery disease.
    Li S; Wu NQ; Zhu CG; Zhang Y; Guo YL; Gao Y; Li XL; Qing P; Cui CJ; Xu RX; Sun J; Liu G; Dong Q; Li JJ
    Atherosclerosis; 2017 May; 260():67-74. PubMed ID: 28351002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy.
    Cao YX; Jin JL; Sun D; Liu HH; Guo YL; Wu NQ; Xu RX; Zhu CG; Dong Q; Sun J; Li JJ
    J Transl Med; 2019 Nov; 17(1):367. PubMed ID: 31711505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of association between lipoprotein(a) and coronary artery calcification in the Genetic Epidemiology Network of Arteriopathy (GENOA) study.
    Kullo IJ; Bailey KR; Bielak LF; Sheedy PF; Klee GG; Kardia SL; Peyser PA; Boerwinkle E; Turner ST
    Mayo Clin Proc; 2004 Oct; 79(10):1258-63. PubMed ID: 15473406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased Aortic Valve Calcification in Familial Hypercholesterolemia: Prevalence, Extent, and Associated Risk Factors.
    Ten Kate GR; Bos S; Dedic A; Neefjes LA; Kurata A; Langendonk JG; Liem A; Moelker A; Krestin GP; de Feyter PJ; Roeters van Lennep JE; Nieman K; Sijbrands EJ
    J Am Coll Cardiol; 2015 Dec; 66(24):2687-2695. PubMed ID: 26700830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mature proprotein convertase subtilisin/kexin type 9, coronary atheroma burden, and vessel remodeling in heterozygous familial hypercholesterolemia.
    Kataoka Y; Harada-Shiba M; Nakao K; Nakashima T; Kawakami S; Fujino M; Kanaya T; Nagai T; Tahara Y; Asaumi Y; Hori M; Ogura M; Goto Y; Noguchi T; Yasuda S
    J Clin Lipidol; 2017; 11(2):413-421.e3. PubMed ID: 28502498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The elevation of plasma concentrations of apoB-48-containing lipoproteins in familial hypercholesterolemia is independent of PCSK9 levels.
    Drouin-Chartier JP; Hogue JC; Tremblay AJ; Bergeron J; Lamarche B; Couture P
    Lipids Health Dis; 2017 Jun; 16(1):119. PubMed ID: 28619117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma proprotein convertase subtilisin/kexin type 9 concentration and recurrent cardiovascular events in patients with familial hypercholesterolemia.
    Cao YX; Liu HH; Jin JL; Sun D; Guo YL; Wu NQ; Zhu CG; Xu RX; Sun J; Santos RD; Li JJ
    Eur J Prev Cardiol; 2021 Apr; 28(3):272-279. PubMed ID: 33891693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.
    Lambert G; Petrides F; Chatelais M; Blom DJ; Choque B; Tabet F; Wong G; Rye KA; Hooper AJ; Burnett JR; Barter PJ; Marais AD
    J Am Coll Cardiol; 2014 Jun; 63(22):2365-73. PubMed ID: 24632287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age-related contribution of Lp(a) with coronary artery calcification in patients with acute coronary syndrome: a potential role of metabolic disorder in calcified plaque.
    Ryu SK; Hong BK; Kwon HM; Kim DS; Chung WJ; Park BE; Kim DY; Cho YH; Yoon SJ; Yoon YW; Cho SY; Kim HS
    Yonsei Med J; 2003 Jun; 44(3):445-53. PubMed ID: 12833582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association of lipoprotein(a) and coronary artery calcium in asymptomatic patients: a systematic review and meta-analysis.
    Martignoni FV; Rl Júnior JE; Marques IR; Gomes C; Moreira VCS; de Souza IAF; Miyawaki IA; Silva CH; do Amaral Neto AB; Padrão EMH; Cardoso R; de Vasconcellos HD; Miedema M
    Eur J Prev Cardiol; 2024 Apr; 31(6):732-741. PubMed ID: 38300625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.